Mutant AKT1-E17K is oncogenic in lung epithelial cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The AKT1 E17K mutation is found in a small percentage of lung cancers.
• Its role as an activating mutation in lung cancer development requires further investigation.

Purpose of the Study:

• To determine if the AKT1-E17K variant is an activating mutation.
• To elucidate the role of AKT1-E17K in lung cancer pathogenesis.

Main Methods:

• Utilized immortalized human bronchial epithelial cells (BEAS-2B).
• Assessed effects of mutant AKT1-E17K on cell proliferation, migration, invasion, and survival.
• Investigated the molecular mechanism involving p27 phosphorylation and localization.
• Correlated cytoplasmic p27 levels with primary non-small cell lung cancers (NSCLCs).

Main Results:

• Mutant AKT1-E17K significantly enhanced anchorage-dependent and -independent proliferation.
• The mutation increased cell migration, invasion, and survival under stress.
• AKT1-E17K oncogenicity involves p27 phosphorylation and cytoplasmic delocalization.
• Cytoplasmic p27 was prevalent in NSCLCs with activated AKT and correlated with poor survival.

Conclusions:

• The AKT1-E17K mutation is a bona-fide activating mutation driving lung cancer.
• This mutation promotes aggressive tumor characteristics and predicts poor patient outcomes.
• Targeting AKT1 signaling could be a therapeutic strategy for lung cancer patients with this mutation.